Detection of MET alterations at the DNA, RNA and protein levels in NSCLC patients progressing on ALK and ROS1 targeted therapies

被引：0
|
作者：
Jordana-Ariza, Nuria [1 ]
Reischmann, Nadine [2 ]
Esparre, Carlos [1 ]
Roman, Ruth [1 ]
Aguado-Esteban, Cristina [1 ]
Garcia-Roman, Silvia [1 ]
Stroh, Christopher [2 ]
Aguilar, Andres Aguilar [1 ]
Rosell, Rafael [1 ]
Karachaliou, Niki [2 ]
Molina-Vila, Miguel A. [1 ]
机构：
[1] Hosp Univ Dexeus, Barcelona, Spain
[2] Merck Healthcare KGaA, Darmstadt, Germany
来源：
CANCER RESEARCH | 2022年 / 82卷 / 12期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1106
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Thrombotic Events at Diagnosis are Associated with Poorer First Line TKI Outcomes Among Metastatic ALK and ROS1 NSCLC Patients
    Sakamoto, M.
    Hu, J.
    Alami, V.
    Watson, A.
    Camidge, R.
    Schenk, E.
    Bunn, P. A.
    Pine, S.
    Patil, T.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S203 - S204
  • [32] Clinical Relevance of ALK/ROS1 Resistance Mutations and Other Acquired Mutations Detected by Liquid Biopsy in Advanced NSCLC Patients
    Mezquita, L.
    Swalduz, A.
    Jovelet, C.
    Ortiz-Cuaran, S.
    Planchard, D.
    Avrillon, V.
    Recondo, G.
    Marteau, S.
    Plagnol, V.
    Howarth, K.
    Morris, C.
    Green, E.
    Lacroix, L.
    Odier, L.
    Rouleau, E.
    Fournel, P.
    Caramella, C.
    Tissot, C.
    Adam, J.
    Perol, M.
    Friboulet, L.
    Saintigny, P.
    Besse, B.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S487 - S488
  • [33] Screening of NSCLC samples from Chinese lung cancer patients for activating rearrangements of the ALK, RET, and ROS1 genes.
    Zheng, Li-Mou
    Whyte, David B.
    Ruan, Li
    Song, Roman
    Fei, Luo
    Yang, Nancy
    Zhou, Caicun
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [34] The landscape of clinically actionable ALK/MET/RET/ROS1 fusions to reveal a shared pattern of protein domains in fusion partners.
    Ritterhouse, Lauren
    Dias-Santagata, Dora
    Nardi, Valentina
    Iafrate, A. John
    Le, Long P.
    Lennerz, Jochen K.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [35] Programmed Cell Death Protein 1 Inhibitors and MET Targeted Therapies in NSCLC With MET Exon 14 Skipping Mutations: Efficacy and Toxicity as Sequential Therapies
    Lau, Sally C. M.
    Perdrizet, Kirstin
    Fung, Andrea S.
    Mata, Danilo Giffoni M. M.
    Weiss, Jessica
    Holzapfel, Nick
    Liu, Geoffrey
    Bradbury, Penelope A.
    Shepherd, Frances A.
    Sacher, Adrian G.
    Feilotter, Harriet
    Field, Brandon Shef
    Hwang, David
    Sound, Ming
    Cheng, Susanna
    Cheema, Parneet
    Leighl, Natasha B.
    JTO CLINICAL AND RESEARCH REPORTS, 2023, 4 (10):
  • [36] A Better Real World Practice for ROS1 Positive NSCLC Patients, Driven by the Targeted Next Generation Sequencing(NGS) and the Targeted TKI
    Liang, Z.
    Zhang, Y.
    Yang, N.
    Li, Y.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S483 - S484
  • [37] Emerging oncogenic fusions other than ALK, ROS1, RET, and NTRK in NSCLC and the role of fusions as resistance mechanisms t o targeted therapy
    Suda, Kenichi
    Mitsudomi, Tetsuya
    TRANSLATIONAL LUNG CANCER RESEARCH, 2020, 9 (06) : 2618 - 2628
  • [38] A study detection of the ROS1 gene fusion by FISH and ROS1 protein expression by IHC methods in patients with ovarian malignant or borderline serous tumors
    Aydin, Hulya Ayik
    Pestereli, Elif
    Ozcan, Mualla
    Bayramoglu, Zeynep
    Erdogan, Gulgun
    Simsek, Tayup
    PATHOLOGY RESEARCH AND PRACTICE, 2018, 214 (11) : 1868 - 1872
  • [39] A Phase I Trial of the MET/ALK/ROS1 Inhibitor Crizotinib Combined with the VEGF Inhibitor Pazopanib in Patients with Advanced Solid Malignancies
    Piha-Paul, Sarina A.
    Dumbrava, Ecaterina E.
    Nair, Binoj C.
    Xiong, Wendy
    Xu, Li
    Mostorino, Rosa
    Subbiah, Vivek
    Tannir, Nizar
    Fu, Siqing
    Naing, Aung
    Janku, Filip
    Karp, Daniel D.
    Patel, Shreyaskumar
    Daw, Najat C.
    Hong, David
    Meric-Bernstam, Funda
    Zinner, Ralph
    ONCOTARGETS AND THERAPY, 2021, 14 : 3037 - 3049
  • [40] Multicenter evaluation of an automated, multiplex, RNA-based molecular assay for detection of ALK, ROS1, RET fusions and MET exon 14 skipping in NSCLC (Mar, 10.1007/s00428-024-03778-9, 2024)
    Melchior, Linea
    Hirschmann, Astrid
    Hofman, Paul
    Bontoux, Christophe
    Concha, Angel
    Mrabet-Dahbi, Salima
    Vannuffel, Pascal
    Watkin, Emmanuel
    Putzova, Martina
    Scarpino, Stefania
    Cayre, Anne
    Martin, Paloma
    Stoehr, Robert
    Hartmann, Arndt
    VIRCHOWS ARCHIV, 2024, 485 (05) : 959 - 959
12345